

## Administrative Management

Angelica Facoetti

Project Meeting – Marburg, May 22<sup>nd</sup>-23<sup>rd</sup>, 2024


Vila Vita Rosenpark Hotel





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

### Where are we?







This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

21/05/2024

### Periodic reporting module – 2<sup>nd</sup> period

Activated **after the end** of each reporting period





All beneficiaries complete their own Financial Statement and their contribution to the Technical Part of the Periodic Report.



Beneficiaries e-sign and submit their Financial Statements to the Coordinator.

The Coordinator approves the elements of the Periodic Report & submits to the EU Services.



EU services review the submitted Periodic Report and accept or reject it.



The PO/ FO may request additional documents/ justifications/ explanations



Approval and Payment

has received funding from the European Union's Horizon 2020 d innovation programme under grant agreement No 101008548

# THANK YOU

Heavy Ion Therapy Research Integration































Project Number: 101008548 Project Acronym: HITRIplus

Project title: Heavy Ion Therapy Research Integration



Periodic Technical Report Part B

Period covered by the report: from 01/10/2022 to 31/03/2024

Periodic report: 2<sup>nd</sup>



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

HILE		ITO
	П	ILE

	PLANATION OF THE WORK CARRIED OUT BY THE BENEFICIARIES AND OVERVIEW OF THE PROGRESS.	
1.2. E	xplanation of the work carried out by each Work Package	1
1.2	.1. Work Package 1 - Project Management	1
1.2	.2. Work Package 2 – NA1 - Networking and communication, dissemination and outreach	1
1.2	.3. Work Package 3 - NA2 - Clinical networking	3
1.2	.4. Work Package 4 - NA3 - Innovation, technology transfer, industry relation	3
1.2	.5. Work Package 5 - NA4 - Education and training	3
1.2	.6. Work Package 6 - Transnational Access (TA)	4
1.2	.7. Work Package 7 - JRA1- Advanced accelerator and gantry design	4
1.2	.8. Work Package 8 - JRA2 - Superconducting magnet design	5
1.2	.9. Work Package 9 - JRA3 - Advanced beam delivery	6
1.2	.10. Work Package 10 - JRA4 - Multiple energy extraction system	6
1.2	.11. Work Package 11 - JRA5 - Controls and Safety	7
1.2	.12. Work Package 12 - JRA6 - Radiobiological Dosimetry and QA	7
1.2	.13. Work Package 13 - Ethics requirement	7
1.3.1	mpact	7
1.4 A	ccess provisions to Research Infrastructures	8
1.4	.1 Description of the publicity concerning the new opportunities for access	8
1.4	.2 Description of the selection procedure	8
1.4	.3 Description of the Trans-National Access activity	8
1.4	.4 Scientific output of the users at the facilities	8
1.4	.5 User meetings	9
1.5	esources used to provide access to Research Infrastructures	9
UP	DATE OF THE PLAN FOR EXPLOITATION AND DISSEMINATION OF RESULT	9
UP	DATE OF THE DATA MANAGEMENT PLAN	9
3.1 F	ollow-up of recommendations and comments from previous review	9
	VIATIONS FROM ANNEX 1 AND ANNEX 2	9
D		_
4.1	Tasks	9

Horizon 2020 o 101008548



Project Number: 101008548 Project Acronym: HITRIplus

Project title: Heavy Ion Therapy Research Integration

**Periodic Technical Report Part B** Annex 1

Period covered by the report: from 01/10/2022 to 31/03/2024

Periodic report: 2<sup>nd</sup>



### **TNA: Trans National Access**

### Research

7 accesses completed in 2 RP





### **Clinical**



21/05/2024



Project Number: 101008548 Project Acronym: HITRIplus

Project title: Heavy Ion Therapy Research Integration

#### Periodic Technical Report Part B Annex 1

Period covered by the report: from 01/10/2022 to 31/03/2024

Periodic report: 2<sup>nd</sup>



### **TNA: Trans National Access**

"Understanding the technology and medical indications specific to Carbon ion therapy prior to sending our own patients there is of paramount importance. Witnessing first-hand the comprehensive approach your team takes in providing state-of-the-art treatment to patients has not only broadened our knowledge but has also equipped us with essential insights into the medical indications that fit treatment at your facility. Your commitment to excellence in patient care and research is truly commendable. Additionally, it was of great importance to us to have the opportunity to visit Mr. Y.L and Mrs. B.K, during their challenging treatments. Witnessing the path and care they are receiving was impressive.

Moreover, witnessing the futuristic carbon ion technology in action was nothing short of impressive. The innovative approaches and cutting-edge technology employed at MedAustron underscore the facility's commitment to pushing the boundaries of medical science and patient care. [...].

Prof. Salem Billan, Dr Roy Holland, Israel

"[...] We strongly believe particle therapy is the future for the Baltic States. [...] The knowledge the experts at CNAO have shared with us allows us to have a better understanding of the intricacies of cancer treatment with protons and especially with carbon ions. We were familiarised with different clinical cases, treatment planning and delivery processes, as well as challenges and future directions for hadrontherapy. The knowledge we have received in CNAO will help us to manage our expectations and envision possibilities regarding the future particle therapy centre in Lithuania or other Baltic states. Therefore, our goal is to establish a close collaborative partnership with CNAO, with a focus on actively participating in patient treatment, clinical research, as well as education and training initiatives."

Julija Joksaite (Lithuania, Medical Physicist).

21/05/2024

### Clinical TNA program Vademecum



#### HITRIplus Clinical Transnational Access Program: Vademecum

#### Who is eligible:

Physicians, particularly oncologists, radiotherapists and medical physicists, and technicians from countries that do not dispose of an hadron accelerator themselves wishing to access to your facility. Special focus on applicants from SEEIIST, Baltics or low incoming countries. Applications can be submitted anytime. Patient involvement is no longer a prerequisite for participation; these accesses focus on clinical research.

#### How to apply:

Individuals or group up to 3 researchers can submit their applications through the online portal: https://www.hitriplus.eu/transnational-access-ca/

#### How to organize the clinical TNA:

The visit may extend up to few days and should be focussed on comparison of treatment plans (photons, C-ions, protons), discussion for C-ion eligibility of clinical cases or for clinical research trials in Hadrontherapy, and active participation in the workflow of hadron treatment.

#### This is an example practiced at CNAO for a 3-days visit:

<u>Day1</u> (afternoon) focused on introduction to the facility and its activities: Welcome and Brief introduction to the facility; Medical Physics activities and research; Clinical Activities and Trials; Radiobiology Research as support to clinical research in Hadrontherapy; Presentation of the R&D Department; The Accelerators, Non-clinical research activities at CNAO and visit to XPR; Final Discussion, Q&A Session

<u>Day2</u> (all day) focused on case studies presented by Radiation Oncologists: and Radiologist: Case Study H&N; Neuro-oncology Case Study; Case Study Sarcomas; Case Study Gynecology; Final Discussion, Q&A Session

Day3 (morning) dedicated to practical sessions at the TPS with medical physicists: Case Study H&N; Neuro-oncology Case Study; Case Study Sarcomas; Case Study Gynecology; Final Discussion, Q&A Session


Remember to collect feedbacks (photos, interviews) for dissemination activities. Moreover, please be reminded that <u>incoming researchers must provide you with a report (1-2 pages)</u>, detailing their learnings and experiences during the days spent at the hosting institution.

#### Cost associated to the Access and reporting:

The HITRIplus funds cover the travel and lodging expenses for the researchers plus the personnel cost involved in the access. A thorough record of all relevant documents pertaining to the expenses incurred for the travel and accommodation of the visiting research groups and all the timesheets of the internal personnel involved in the access must be collected. These timesheets serve as a critical element in determining the actual costs incurred during the access period by the hosting institution. Please, consider in these timesheets also administrative and clinical staff that work for the access not only during the days of the visit, but also in preparation of it. To enhance clarity in reporting, we recommend that the hosting infrastructure directly pay the expenses for travel and accommodation. Indeed, it is essential for invoices to reference the HITRIplus project GA 101008548

If you need assistance please refer to: Angelica Facoetti: Facoetti@cnao.it; Chiara Marazzi: Marazzi@cnao.it







This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

21/05/2024 7

WP No	Del Rel. N	Del No	Title	Description		Lead B	Nature	Dissemina	
WP1	D1.1	D1	All governance boards instal	The General Assembly (GA), the Technical Proje 🗖	]	CNAC	Report	Public	
WP2	D2.1	D4	Dissemination to the comm	Inform medical and research communities about t 🗖		CNAC	Report	Public	
WP1	D1.3	D3	Data Management Plan	The data management plan describing the data ma 🗖		CNAC	Report	Public	
WP13	D13.1	D39	H - Requirement No. 1	The procedures and criteria that will be used t 🗖		CNAC	Ethics	Confide	
WP10	D10.1	D30	Beam Characteristics Library	Generation of a beam Characteristics Library op $lacktriangle$	Г	40		4.	· · ·
WP9	D9.1 D27 Conceptual Design Report ft From market and literature research, recommenda⊟		_	<b>1°</b>	reporting p		eriod		
WP8	WP8 D8.1 D24		Magnet Assessment for SC a	Report on assessment of magnet types, suitable 🗖			(11		
WP3	D3.1	D7	Review of promising innovat	Review of promising innovative heavy ion therap 🗖		MED4	Report	Public	
WP6	D6.1	D18	HITRIplus delivers 100 hrs of	HITRIplus delivers 100 hrs of research TNA by m □		GSI	Report	Public	
WP11	D11.1	D33	Design study on novel treat	Design novel treatment control system, which wi 🗖		CSL	Demons	Public	
WP10	D10.2	D31	Data Distribution and Synch	Definition of the data distribution and synchro $lacktriangle$		UKHE	Report	Confide	
WP5	D5.1	D14	Delivery of specialised train	Delivery of two one-week training courses on he 🗖 🧵		SEEII	Website	Public	
WP5	D5.4	D17	Organisation of secondment	Organisation of secondments and internships in $\ldots$		UM	Website	Public	
WP7	D7.1	D21	Linac injector design	Advanced conceptual design of an optimised lina 🗖	_	BEVA	Report	Confide	
WP9	D9.2	D28	Particle arc therapy delivery	Using the demonstrator from M9.1, a particle ar 🗖		<b>2°</b>	repor	ting p	eriod
WP4	D4.1	D11	HITRIplus technologies and	Internal report collecting and describing the $t$				3/9)	
WP4	D4.2	D12	Value propositions	Promotional text and visual material aimed at d 🗖	L			,,,,,	
WP5	D5.3	D16	Provision of e-learning cours	Conversion of the training courses and mastercl 🗖		UM	Website	Public	
WP10	D10.3	D32	Real-Time Data Generation 9	Realization of a quasi-real time data supply mo 🗖 💆	Į	UKHE	Report	Confide	
WP8	D8.2	D25	TDR (Technical Design Repor	Final report on Magnet design for SC synchrotro 🗖		INFN	Report	Confide	
WP3	D3.2	D8	Web based heavy ion therap	Web based heavy ion therapy patient registry wi… 🗖		CNAC	Website	Confide	
WP3	D3.4	D10	Trial protocol for innovative	Definition of a pilot clinical trial protocol t 🗖		MED/	Report	Public	
WP4	D4.3	D13	Technology matching event	Organisation of an event targeted at industry, 🗖		INFN	Report	Public	
WP7	D7.2	D22	Gantry design	Report describing the main optics parameters an 🗖		CNAC	Report	Confide	
WP12	D12.1	D36	Conceptual design report ar	Generation of standard operating procedure (SOP $lacktriangle$		UMR	Report	Public	
WP7	D7.3	D23	SC synchrotron design	Design of an optimised synchrotron with SC magn 🗖		SEEII	Report	Public	
WP11	D11.2	D34	Design study on novel accel	Design novel accelerator control system with st 🗖		CSL	Report	Public	
WP12	D12.2	D37	Modelling of the joint result	Transfer of results from D12.1 to UKHD/HIT for 🗖		UKHE	Report	Public	
WP2	D2.2	D5	Dissemination and outreach	Outreach programme for events -1 per year. HITR 🗖	LΓ	3°	rone	ortina	period
WP8	D8.3	D26	Magnet Demonstrator	Completion of the magnet demonstrator with coil 🗖		3		_	periou
WP9	D9.3	D29	Identification of beneficial	Patient plans with dosimetric benefits will be □				(0/20)	
WP2	D2.3	D6	Provide an annual activity re	Activity report annually The delivery date assi 🗖		SEEII	Report	Public	
WP11	D11.3	D35	Design study on novel patie	Design novel patient safety system, which will 🗖		CSL	Report	Public	
WP12	D12.3	D38	Final report and summary	Results will be summed up and distributed betwe 🗖		UMR	Report	Public	
WP5	D5.2	D15	Delivery of masterclasses an	Delivery of a one week training course on heavy 🗖		GSI	Website	Public	
WP1	D1.2	D2	Plenary meetings reports	Reports of the plenary meetings. The delivery d 🗖		CNAC	Report	Public	
WP3	D3.3	D9	Dose constraints of OARs in	Dose constraints of OARs in use at European hea 🗖		UKHE	Report	Public	
WP6	D6.2	D19	HITRIplus delivers 498 units	Description of TA units delivered by month 54 w 🗖		GSI	Report	Public	
WP6	D6.3	D20	Publication of an overview a	Publishing the results of the TA regarding expe □		GSI	Report	Public	



### **Deliverables**



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

### **Milestones**



lestones	s				
Number	Name	Lead Beneficiary	Delivery Date (Annex I)	Achieved	C Comments
11	Intermediate report on the state-of-the-art treatment room, acceler	CSL	31 Mar 2022	<	An internal report providing an overview of th
7	Linac and Gantry conceptual design, and SC synchrotron main parame	CERN	31 Mar 2022	✓	An internal report describing the basic paramet
5	Specialised Courses and masterclasses content definition	SEEIIST	30 Sep 2022	✓	The goal of WP5 is to increase the European Poo
14	Evaluation of web based registry development status	MEDA	30 Sep 2022	✓	A proposal for a web based registry to provide
1	Mid-term General Assembly Meeting completed	CNAO	30 Sep 2022	✓	The HITRplus mid-term General Assembly meeting
9	Finished simulation environment for particle arc therapy	GSI	30 Sep 2022	✓	The completion of the simulation setup for part
8	Magnet Layout decision and Engineering design	INFN	30 Nov 2022	✓	After the design comparison study (deliverable
10	Real-Time Data Generation Strategy	UKHD	30 Nov 2024		

31 Jan 2025

31 Mar 2025

UMR

MEDA

Horizon 2020

research and innovation programme under grant agreement No 101008548

Heavy Ion Therapy Research Integration

)

Generation of a standardized dosimetry for collaborative radiobiologic

Evaluation of impact on European centres OARs constraints

# THANK YOU!





https://www.hitriplus.eu/



**@HITRIplus - Heavy Ion Therapy Research Integration** 



**HITRIplus** 



@heavy\_ion



**HITRIplus** 



